Immunome (IMNM) Profit After Tax (2019 - 2026)
Immunome's (IMNM) quarterly Profit After Tax came in at -$53.8 million in Q1 2026, down 29.3% YoY from -$76.1 million in Q1 2025, and up 22.98% on a QoQ basis from -$69.9 million in Q4 2025.
Immunome (IMNM) Profit After Tax (2019 - 2026) Analysis & Trends
Immunome (IMNM) has 8 years of Profit After Tax data on file, last reported at -$53.8 million in Q1 2026.
- Quarterly Profit After Tax fell 29.3% year-over-year to -$53.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$224.6 million (down 9.5% YoY) and the FY2025 annual result came in at -$212.4 million, up 27.5% from the prior year.
- Profit After Tax advanced to -$53.8 million in Q1 2026, from -$69.9 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$4.3 million in Q1 2023 to a low of -$129.5 million in Q1 2024.
- A 5-year average of -$41.4 million and a median of -$41.6 million in 2025 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2024 — Profit After Tax slumped 2932.6% — and 2025, when it jumped 67.84%.
- Tracing IMNM's Profit After Tax over 5 years: stood at -$8.4 million in 2022, then sank by 1000.43% to -$92.6 million in 2023, then rose by 13.37% to -$80.2 million in 2024, then rose by 12.9% to -$69.9 million in 2025, then grew by 22.98% to -$53.8 million in 2026.
- The last three Profit After Tax figures came in at -$53.8 million (Q1 2026), -$69.9 million (Q4 2025), and -$57.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - | -73.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -73.13 Mn |
| Mar 31, 2026 | -53.84 Mn |
| Dec 31, 2025 | -69.90 Mn |
| Sep 30, 2025 | -57.46 Mn |
| Jun 30, 2025 | -43.40 Mn |
| Mar 31, 2025 | -41.64 Mn |
| Dec 31, 2024 | -80.25 Mn |
| Sep 30, 2024 | -47.10 Mn |
| Jun 30, 2024 | -36.12 Mn |
| Mar 31, 2024 | -129.49 Mn |
| Dec 31, 2023 | -92.63 Mn |
| Sep 30, 2023 | -4.35 Mn |
| Jun 30, 2023 | -5.56 Mn |
| Mar 31, 2023 | -4.27 Mn |
| Dec 31, 2022 | -8.42 Mn |
| Sep 30, 2022 | -8.53 Mn |
| Jun 30, 2022 | -8.92 Mn |
| Mar 31, 2022 | -11.65 Mn |
| Dec 31, 2021 | -7.84 Mn |
| Sep 30, 2021 | -7.72 Mn |